Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$210.12 USD

210.12
983,441

+12.55 (6.35%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Invest in IDEXX (IDXX) Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.

Bruker's (BRKR) Latest Workflows to Aid Applied Markets

by Zacks Equity Research

Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.

Here's Why You Should Invest in Edward Lifesciences (EW) Now

by Zacks Equity Research

Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.

LabCorp (LH) Expands Precision Oncology With Biopsy Test

by Zacks Equity Research

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

by Zacks Equity Research

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.

Here's Why You Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome (Revised)

by Zacks Equity Research

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.

Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio

by Zacks Equity Research

Myriad Genetics (MYGN) expands Precise Oncology Solutions portfolio by adding a new biomarker test.

Here's Why You Should Retain Bruker (BRKR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.

Boston Scientific (BSX) Gains From Acquisitions, New Launches

by Zacks Equity Research

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker

by Zacks Equity Research

Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.

Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome

by Zacks Equity Research

Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs

by Zacks Equity Research

Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.

Zacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment

by Zacks Equity Research

Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment have been highlighted in this Screen of The Week article.

Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays

by Zacks Equity Research

Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.

Nilanjan Banerjee headshot

Buy These 4 Low-Beta Stocks to Sail Through Market Volatility

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and AeroVironment (AVAV) are poised to gain.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG